JPMorgan Chase & Co. Issues Pessimistic Forecast for iRhythm Technologies (NASDAQ:IRTC) Stock Price

iRhythm Technologies (NASDAQ:IRTC) had its price target decreased by equities research analysts at JPMorgan Chase & Co. from $240.00 to $215.00 in a research note issued to investors on Friday,Benzinga reports. The brokerage currently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price objective suggests a potential upside of 42.42% from the company’s previous close.

A number of other research firms have also commented on IRTC. Citigroup upped their price objective on shares of iRhythm Technologies from $205.00 to $242.00 and gave the company a “buy” rating in a research note on Friday, October 31st. BTIG Research upped their price target on shares of iRhythm Technologies from $195.00 to $215.00 and gave the company a “buy” rating in a research report on Friday, October 31st. Evercore upgraded iRhythm Technologies from an “in-line” rating to an “outperform” rating and increased their price target for the stock from $194.00 to $210.00 in a report on Monday, January 5th. The Goldman Sachs Group lifted their price objective on iRhythm Technologies from $180.00 to $202.00 and gave the stock a “neutral” rating in a research report on Friday, October 31st. Finally, Needham & Company LLC restated a “buy” rating and set a $244.00 target price on shares of iRhythm Technologies in a research report on Monday, January 12th. Two research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $211.62.

iRhythm Technologies Trading Down 5.0%

NASDAQ IRTC opened at $150.96 on Friday. The firm has a market capitalization of $4.86 billion, a PE ratio of -107.83 and a beta of 1.06. The business’s 50-day moving average price is $164.65 and its two-hundred day moving average price is $171.37. The company has a current ratio of 4.63, a quick ratio of 4.50 and a debt-to-equity ratio of 5.32. iRhythm Technologies has a 12 month low of $92.52 and a 12 month high of $212.00.

iRhythm Technologies (NASDAQ:IRTC) last posted its quarterly earnings data on Thursday, February 19th. The company reported $0.29 EPS for the quarter, topping analysts’ consensus estimates of $0.02 by $0.27. The company had revenue of $208.89 million for the quarter, compared to analyst estimates of $202.61 million. iRhythm Technologies had a negative return on equity of 31.44% and a negative net margin of 5.96%.The firm’s quarterly revenue was up 27.1% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.04) earnings per share. On average, analysts expect that iRhythm Technologies will post -1.98 EPS for the current year.

Insider Activity

In related news, insider Patrick Michael Murphy sold 2,478 shares of the company’s stock in a transaction that occurred on Tuesday, December 2nd. The stock was sold at an average price of $184.83, for a total transaction of $458,008.74. Following the transaction, the insider directly owned 53,281 shares of the company’s stock, valued at approximately $9,847,927.23. This represents a 4.44% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Chad Patterson sold 280 shares of the firm’s stock in a transaction that occurred on Tuesday, December 2nd. The shares were sold at an average price of $184.83, for a total value of $51,752.40. Following the completion of the sale, the insider directly owned 43,387 shares of the company’s stock, valued at $8,019,219.21. This trade represents a 0.64% decrease in their position. The disclosure for this sale is available in the SEC filing. Company insiders own 1.10% of the company’s stock.

Hedge Funds Weigh In On iRhythm Technologies

A number of institutional investors have recently modified their holdings of the company. Measured Wealth Private Client Group LLC bought a new stake in iRhythm Technologies during the 3rd quarter valued at $30,000. Root Financial Partners LLC acquired a new position in shares of iRhythm Technologies during the third quarter valued at about $30,000. GAMMA Investing LLC raised its holdings in shares of iRhythm Technologies by 48.4% in the 4th quarter. GAMMA Investing LLC now owns 184 shares of the company’s stock worth $33,000 after acquiring an additional 60 shares during the last quarter. Smartleaf Asset Management LLC lifted its position in iRhythm Technologies by 100.0% in the 3rd quarter. Smartleaf Asset Management LLC now owns 198 shares of the company’s stock valued at $34,000 after acquiring an additional 99 shares in the last quarter. Finally, FNY Investment Advisers LLC acquired a new position in iRhythm Technologies during the 3rd quarter valued at about $34,000.

iRhythm Technologies News Roundup

Here are the key news stories impacting iRhythm Technologies this week:

• Positive Sentiment: Q4 results beat estimates — Revenue $208.9M (+27.1% YoY) and EPS $0.29 topped consensus; management reported record quarterly revenue, improved gross margin and positive GAAP net income for the quarter. Globe Newswire: Q4 Results
• Positive Sentiment: Beating the street — Third‑party coverage highlights the earnings and revenue beat and improved profitability metrics (adjusted EBITDA, cash flow). These operational improvements support upside case over time. Zacks: Earnings Beat
• Neutral Sentiment: Company materials available — Earnings call transcript and slide deck published for investors to evaluate management commentary and forward drivers (AC C presentations and upcoming data cadence). Useful for confirming guidance/assumptions. Seeking Alpha: Call Transcript
• Neutral Sentiment: Market coverage noted positive market reaction after the print in some outlets — short-term sentiment can swing quickly as investors parse details. MassDevice: Market Reaction
• Negative Sentiment: Analysts trimmed price targets across several firms today (Canaccord, JPMorgan, Wells Fargo, Robert W. Baird) — ratings remain generally positive/overweight but lower targets reduce near‑term upside expectations and can pressure the stock. Benzinga: Analyst Target Changes
• Negative Sentiment: Insider selling and institutional rebalancing highlighted — multiple insider sales and large shifts in fund holdings raise concern about near-term selling pressure and supply overhang. Quiver: Insider & Institutional Activity

iRhythm Technologies Company Profile

iRhythm Technologies, Inc is a medical technology company that develops and commercializes wearable cardiac monitoring devices and associated data analytics services. Founded in 2006 and headquartered in San Francisco, California, the company’s flagship product is the Zio® patch, a discreet, single-use, continuous ECG recorder designed to monitor heart rhythms for up to 14 days. iRhythm’s digital diagnostics platform combines biosensor technology with proprietary algorithms to detect arrhythmias and streamline data interpretation for physicians.

The Zio service is prescribed by cardiologists and other healthcare providers to aid in the diagnosis of atrial fibrillation, bradycardia, tachycardia and other rhythm disorders.